Effect of Zinc Supplementation on Gestational Diabetes

Effect of Zinc Supplementation on Insulin Resistance, Metabolic and Inflammatory Indices in non Diabetic Pregnant Women with Impaired Glucose Tolerance

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201212265670N6

Enrollment

Registered

2013-04-10

Start date

2013-04-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus. Diabetes mellitus arising in pregnancy

Interventions

Intervention 1: Intervention:Tab Zinc Guconate 30 mg/once a day for 2 month In intervention group 23 pregnant women after the entry qualifications will take one tablet of Zinc Gluconate for 2 month an

Treatment - Drugs

Intervention:Tab Zinc Guconate 30 mg/once a day for 2 month In intervention group 23 pregnant women after the entry qualifications will take one tablet of Zinc Gluconate for 2 month and variables wil

Control: Placebpo/once a day for 2 month/In control group 23 pregnant women after the entry qualifications will take one tablet of placebo for 2 month and variables will be analysed before and after t

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: 1. Pregnant women with abnormal OGTT screening test. Exclusion criteria: 1. History of Diabetes Mellitus before the current pregnancy. 2. Infection, chronic diseases, medicinal therapy, anemia. 3. History of gestational diabetes in previous pregnancy. 4. Smoking and/or alcohol consumption. 5. History of zinc supplementation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Glucose. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.;Serum Insulin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Insulin Resistancy. Timepoint: Before and After the Intervention. Method of measurement: HOMA-IR.;Serum Leptin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Visfatin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Zinc-a2 - Glycoprotein. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Fasting Blood Glucose. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.;1 hour Blood Sugar. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.;2 hour Blood Sugar. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.	—

Measure

Time frame

Serum Glucose. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.;Serum Insulin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Insulin Resistancy. Timepoint: Before and After the Intervention. Method of measurement: HOMA-IR.;Serum Leptin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Visfatin. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Zinc-a2 - Glycoprotein. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before and After the Intervention. Method of measurement: ELISA.;Fasting Blood Glucose. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.;1 hour Blood Sugar. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.;2 hour Blood Sugar. Timepoint: Before and After the Intervention. Method of measurement: Enzymatic.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026